The two most widely used antiplatelet drugs in the world are aspirin and clopidogrel.
However, some patients on aspirin and/or clopidogrel therapy do not respond appropriately to …

Etranacogene dezaparvovec (AMT-061) is a recombinant adeno-associated virus serotype 5
(AAV5) vector containing a codon-optimized Padua variant human factor IX (FIX) transgene …

Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII
cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A (HA). …

The treatment of hemophilia consists of clotting factor replacement to prevent and control
bleeding. The development of an inhibitor is one of the most serious complications of the …

Gray platelet syndrome (GPS) is a rare recessive disorder caused by biallelic variants in
NBEAL2 and characterized by bleeding symptoms, the absence of platelet α-granules, …

FcRn plays a major role in regulating immune homeostasis, but it is also able to transport
biologics across cellular barriers. The question of whether FcRn could be an efficient …

Introduction Pneumatic tube system (PTS) in hospitals is commonly used for the transport of
blood samples to clinical laboratories, as it is rapid and cost-effective. The aim was to …

… Sandra Le Quellec, Sandra Le Quellec … Sandra Le Quellec, Claude Negrier;
Emicizumab should be prescribed independent of immune tolerance induction. Blood Adv …

Background Etranacogene dezaparvovec, the first gene therapy approved for haemophilia
B treatment, was shown to be superior to treatment with continuous prophylactic factor IX in …

Introduction The development of inhibitory antibodies is a severe complication of clotting
factor replacement therapy in patients with severe haemophilia A (HA). Current World …